Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Activating Mutation”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05074810
What this trial is testing

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 153
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Not applicableAvailableNCT04566393
What this trial is testing

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Who this might be right for
Pancreatic CancerSmall Bowel CancerColorectal Cancer+18 more
xCures
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Testing effectiveness (Phase 2)Study completedNCT04620330
What this trial is testing

Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 90
Testing effectiveness (Phase 2)WithdrawnNCT04470674
What this trial is testing

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Who this might be right for
Lung CancerNon-small Cell Lung CancerPD-L1 Gene Mutation+1 more
Shirish M Gadgeel
Testing effectiveness (Phase 2)Active Not RecruitingNCT05375994
What this trial is testing

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerKRAS Activating MutationAdvanced Cancer+3 more
Verastem, Inc. 85
Testing effectiveness (Phase 2)Study completedNCT06208124
What this trial is testing

IMM-6-415 in RAS/RAF Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)Pancreas AdenocarcinomaNon-small Cell Lung Cancer+1 more
Immuneering Corporation 30
Large-scale testing (Phase 3)Active Not RecruitingNCT01933932
What this trial is testing

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Who this might be right for
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca 510
Testing effectiveness (Phase 2)Active Not RecruitingNCT05039177
What this trial is testing

ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma
Erasca, Inc. 102
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05669482
What this trial is testing

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

Who this might be right for
KRAS Activating MutationMetastatic CancerPancreas Cancer+2 more
Verastem, Inc. 40